FDA Reviewer Retention Remains Priority In FY 2001 - User Fee Report
This article was originally published in The Tan Sheet
Executive Summary
FDA will implement ideas from employee focus groups in FY 2001 to try to improve the retention rate in its drug review divisions, the agency said in its fiscal 2000 Prescription Drug User Fee Act Financial Report.
You may also be interested in...
CDER deputy director
A candidate has been identified, but announcement has been postponed due to the Bush Administration's hiring freeze, Office of Pharmaceutical Science Acting Director Helen Winkle told NAPM annual meeting attendees in Las Croabas, Puerto Rico Jan. 31. Prospective deputy is not an agency employee, but "he will do a lot for the center in helping to promote the activities that are going on," Winkle said
Hiring Freeze Will Affect FDA Commissioner, ORM Director Appointments
Acting FDA Commissioner Bernard Schwetz, PhD, will continue to make funding the agency's science base a top priority, he stresses in a Jan. 22 email to agency staff.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC